Article Versions Notes

Rodríguez-García A, Morales ML, Garrido-García V, García-Baquero I, Leivas A, Carreño-Tarragona G, Sánchez R, Arenas A, Cedena T, Ayala RM, et al. Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy. Antioxidants. 2019; 8(11):508. https://doi.org/10.3390/antiox8110508

Rodríguez-García, Alba, María Luz Morales, Vanesa Garrido-García, Irene García-Baquero, Alejandra Leivas, Gonzalo Carreño-Tarragona, Ricardo Sánchez, Alicia Arenas, Teresa Cedena, Rosa María Ayala, and et al. 2019. "Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy" Antioxidants 8, no. 11: 508. https://doi.org/10.3390/antiox8110508

Rodríguez-García, A., Morales, M. L., Garrido-García, V., García-Baquero, I., Leivas, A., Carreño-Tarragona, G., Sánchez, R., Arenas, A., Cedena, T., Ayala, R. M., Bautista, J. M., Martínez-López, J., & Linares, M. (2019). Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy. Antioxidants, 8(11), 508. https://doi.org/10.3390/antiox8110508